Forest Laboratories Inc., maker of the Alzheimer’s drug Namenda, will buyAptalis Pharma for $2.9 billion, adding treatments for gastrointestinal ailments and cystic fibrosis.

Aptalis, a closely-held company whose shareholders include investment firm TPG Capital, generated $688 million in sales in the 12 months ended in September, New York-based Forest said in a statement today. The all-cash deal is expected to close in the first half of this year, Forest said.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.